Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company's ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014. Oramed CEO Nadav Kidron will present the findings at an investor conference taking place at the Tel Aviv Stock Exchange in Tel Aviv, Israel.
The Phase 2a trial was conducted in the U.S. under the auspices of the FDA and was designed to show the drug's overall safety profile. Thirty patients with type 2 diabetes took part in the double-blind, randomized trial in an in-patient setting for one week of treatment.
Restoring insulin sensitivity without TZD side effects